RS20050484A - Lek, u obliku praha za inhalaciju, koji sadrži so tiotropijuma i salmeterolksinafoat - Google Patents

Lek, u obliku praha za inhalaciju, koji sadrži so tiotropijuma i salmeterolksinafoat

Info

Publication number
RS20050484A
RS20050484A YUP-2005/0484A YUP20050484A RS20050484A RS 20050484 A RS20050484 A RS 20050484A YU P20050484 A YUP20050484 A YU P20050484A RS 20050484 A RS20050484 A RS 20050484A
Authority
RS
Serbia
Prior art keywords
inhalation
salmeterol xinafoate
tiotropium salt
powdered medicament
treatment
Prior art date
Application number
YUP-2005/0484A
Other languages
English (en)
Inventor
Hagen Graebner
Heimel Mareke Hartig
Peter Sieger
Rainer Soyka
Michael Trunk
Michael Walz
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20050484(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg., filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.,
Publication of RS20050484A publication Critical patent/RS20050484A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pronalazak se odnosi na preparate u obliku praha za inhaliranje, koji sadrže so tiotropijuma i salmeterolksinafoat, na postupak za njihovo pripremanje kao i na njihovu primenu za pripremanje leka za lečenje oboljenja disajnih puteva, naročito za tretiranje COPD-a (chronic obstructive pulmonary disease = hronično opstruktivno oboljenje pluća) i astme.
YUP-2005/0484A 2002-12-20 2003-12-04 Lek, u obliku praha za inhalaciju, koji sadrži so tiotropijuma i salmeterolksinafoat RS20050484A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20
PCT/EP2003/013691 WO2004058233A1 (de) 2002-12-20 2003-12-04 Pulverförmige arzneimittel zur inhalation enthaltend ein tiotropiumsalz und salmeterolxinafoat

Publications (1)

Publication Number Publication Date
RS20050484A true RS20050484A (sr) 2007-11-15

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0484A RS20050484A (sr) 2002-12-20 2003-12-04 Lek, u obliku praha za inhalaciju, koji sadrži so tiotropijuma i salmeterolksinafoat

Country Status (21)

Country Link
EP (1) EP1581198A1 (sr)
JP (1) JP2006516135A (sr)
KR (1) KR20050086930A (sr)
CN (1) CN1728988B (sr)
AU (1) AU2003288226B2 (sr)
BR (1) BR0317443A (sr)
CA (1) CA2510779A1 (sr)
DE (1) DE10351663A1 (sr)
EA (1) EA010588B1 (sr)
EC (1) ECSP055855A (sr)
FR (1) FR2848849B1 (sr)
HR (1) HRP20050570A2 (sr)
IT (1) ITMI20032473A1 (sr)
MX (1) MXPA05006519A (sr)
NO (1) NO20053548L (sr)
NZ (1) NZ541303A (sr)
PL (1) PL376231A1 (sr)
RS (1) RS20050484A (sr)
UA (1) UA83813C2 (sr)
WO (1) WO2004058233A1 (sr)
ZA (1) ZA200503692B (sr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
EP1959942A1 (en) * 2005-08-06 2008-08-27 Boehringer Ingelheim International GmbH Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
CN102731494A (zh) * 2005-12-19 2012-10-17 西科尔公司 噻托溴铵的新形式及其制备方法
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
DE102007036411A1 (de) * 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
PE20090907A1 (es) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
CA3119145A1 (en) 2018-11-13 2020-05-22 Cocrystal Pharma, Inc. Formulations comprising 3-(2-(5-chloro-1h-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7h-pyrrolo[2,3-d]pyrimid-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid for the treatment of influenza

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法
AU1229892A (en) * 1992-02-11 1993-09-03 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
DE10104367A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
EP1416990A1 (en) * 2001-08-09 2004-05-12 Glaxo Group Limited Inhalation device with a pharmaceutical composition
WO2003024452A1 (de) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur inhalation

Also Published As

Publication number Publication date
CN1728988A (zh) 2006-02-01
EA200500902A1 (ru) 2006-02-24
ITMI20032473A1 (it) 2004-06-21
ECSP055855A (es) 2005-11-22
JP2006516135A (ja) 2006-06-22
ZA200503692B (en) 2006-10-25
FR2848849A1 (fr) 2004-06-25
AU2003288226A1 (en) 2004-07-22
MXPA05006519A (es) 2005-08-26
WO2004058233A1 (de) 2004-07-15
BR0317443A (pt) 2005-11-16
HRP20050570A2 (en) 2006-07-31
EA010588B1 (ru) 2008-10-30
CA2510779A1 (en) 2004-07-15
NO20053548L (no) 2005-09-02
PL376231A1 (en) 2005-12-27
AU2003288226B2 (en) 2010-01-07
CN1728988B (zh) 2010-04-28
FR2848849B1 (fr) 2007-01-05
UA83813C2 (ru) 2008-08-26
KR20050086930A (ko) 2005-08-30
NZ541303A (en) 2008-11-28
EP1581198A1 (de) 2005-10-05
DE10351663A1 (de) 2004-07-01

Similar Documents

Publication Publication Date Title
RS20050484A (sr) Lek, u obliku praha za inhalaciju, koji sadrži so tiotropijuma i salmeterolksinafoat
MY123544A (en) New inhalable powder containing tiotropium
MY155912A (en) New inhalable powder containing tiotropium
MEP30108A (en) Formoterol superfine formulation
TW200708513A (en) Novel crystalline forms of tiotropium bromide
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
CY1114157T1 (el) Αλατα του τιοτροπιου, μεθοδος για την παραγωγη τους και φαρμακευτικα σκευασματα που τα περιεχουν
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
SG149876A1 (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
IL199022A0 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
IL189182A0 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
MXPA04002401A (es) Nuevos medicamentos para inhalacion.
MXPA04007294A (es) Composicion para inhalacion.
DK1494648T3 (da) Pulverpræparat til inhalation
WO2005007134A8 (de) Pulverformulierungen für die inhalation enthaltend ein neues anticholinergikum
ZA200801407B (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma